Oncology Exploration Center By Alcimed

Alcimed supported a top pharma player in defining the strategy of an early asset in rare cancer indication.

We helped our client to understand the current treatment pathways in addition to needs and challenges linked to it, identified trends in the indication, and aimed to understand how these trends and underlying future technologies will impact the current treatment pathway and shape it in the future. We also worked on the evaluation of direct and indirect competitors and collaborated on the development of the short- and mid-term asset strategies.

Our work allowed our client to optimally plan clinical trials and prepare the launch of the asset.

Alcimed supported a pharma player in preparing the launch of their new oncology product for pediatric patients in Germany.

We helped them to understand the treatment pathway of childhood cancer in general from diagnosis to treatment to monitoring, even after children become adolescent. We identified key blocking points along the pathways, and mapped treatment and diagnosis centers and key stakeholders in Germany. This included patient associations, physicians, or social workers and allowed our client to optimally plan activities to support the launch of the new drug.

Alcimed supported a leading stakeholder in the field of CAR-T cells in preparing for the launch of its new treatment and in defining its market access strategy in the United States, Canada and Europe.

CAR-T cells are highly personalized technologies that require a high level of specialization to be delivered to patients, and therefore not all healthcare facilities are ready to administer them. In this context, and in order to define the market access strategy for its new treatment, we helped our client to understand and identify which centers would have the capacity to deliver CAR-T cells, among more than 200 care centers in the United States, Canada and Europe.

Then, the analysis of the barriers to approval in the relevant markets made it possible to define the actions to be implemented to develop the skills of each center, and thus ensure access to their new CAR-T cell therapy.

Alcimed supported a medical device player in building adequate business models of a new intraoperative surgical technology for cancer.

We identified the most relevant launch countries for the technology and analyzed the value of the technology for stakeholders in the scope countries, where we took into account country-specific funding mechanisms of surgeries and medical equipment. Then, Alcimed identified potential direct and indirect competitors, analyzed pressure from these players, and analyzed the commercialization potential according to needs, competitive pressure, and pricing.

Alcimed supported a pharmaceutical player to analyze the opportunities to invest into the immuno-oncology field.

We reviewed the different types of immunotherapies in cancer treatments to understand products in development, products commercialized, study on the partnerships/deals, and helped our client to estimate the market attractiveness for specific indications – notably, by reviewing pipelines and strategies of main actors, and rising stars in this field.

Alcimed supported a client in deciding the future of colorectal cancer biomarkers and the potential of a new screening biochip.

Alcimed carried out a qualitative analysis of the current and future needs of GPs and specialists who are involved in the diagnosis of colorectal cancer, as well as analyzing the strengths and weaknesses of our client offer compared to existing diagnosis methods and future molecular tests.

Alcimed supported a global pharma player in in improving mCRPC treatment processes and workflows in Nuclear Medicine Centers (NMC) in Europe.

We helped our client by analyzing data from observations within 11 European key NMC and gathered insight into the key barriers, best practices, tools, and services that are applied in these centers. All centers gathered in an international workshop, developed means to share best practices across all European treatment centers, and published the results in an international publication. As a next step, Alcimed followed up with several centers in order to understand the level of implementation of specific solutions and their impact of the work flow in NMCs in Europe. Lastly, the entire analysis expanded to a total of around 50 European centers, and tools and outputs were enriched and updated.

The entire project helped European centers to optimize their treatment processes.

Alcimed supported a client in imagining and building a brand new conviction system for its 5 future launches in hemato-oncology.

We supported our client in understanding their expectations and needs around access to information, digital tools, and interaction with the industry and with other healthcare professionals. We then identified criteria considered important in the decision-making process of prescription in different product contexts. Finally, our team benchmarked surrogates within the pharma industry and supported our client in co-building a new conviction-engagement model.

Alcimed supported a pharma player to investigate the Immunogenic cell death (ICD) field to find future therapeutic treatments for cancer patients. Our client aimed to develop a drug for a defined population of cancer patients where their ICD fails, in order to enhance it and make it work again.

To support our client, Alcimed evaluated three potential subfields in ICD, and showed which induction field is highly developed based on scientific rationales. Next, we mapped research global hotspots and evaluated their maturity. Finally, we evaluated the maturity and progress of key players, and assessed partnership opportunities for the client.

The recommendations allowed our client to identify potential partners to collaborate with in future drug development, and the results served as base for their future strategic orientation.